Cancer Immunotherapy Market Analysis North America,Europe,Asia,Rest of World (ROW) - US,Canada,Germany,France,China - Size and Forecast 2023-2027

Published: Oct 2023

Pages: 168

SKU: IRTNTR71598

Snapshot

Cancer Immunotherapy Market Forecast 2023-2027

The global cancer immunotherapy market size is estimated to grow by USD 38.57 billion at a CAGR of 7.42% between 2022 and 2027. The high prevalence of cancer worldwide is increasing the demand for effective treatment options, driving the growth of the market. Growing awareness among consumers regarding the benefits of cancer immunotherapy, which offers targeted and personalized treatment options with potentially fewer side effects, is also driving market growth. Additionally, the strong R&D pipeline of monoclonal antibodies, which are a key component of many cancer immunotherapy treatments, is fueling innovation in the field and expanding treatment options for patients. Overall, these factors are creating a favorable market environment for cancer immunotherapy and driving advancements in cancer treatment.

The research and development pipeline of monoclonal antibodies is dominated by cancer immunotherapy system indications. Among these, in view of increasing cancer prevalence and the high uptake of monoclonal antibodies as treatment options, oncology appears to be a major therapeutic area for monoclonal antibodies. Both large and small players are investing in the development of monoclonal antibodies, but Novartis has the largest pipeline for monoclonal antibodies. However, a very small fraction of monoclonal antibodies in R&D programs have reached the clinical and marketing phases for anti-infection and neuropharmacological monoclonal antibodies. The adoption of novel therapeutics in cancer immunotherapy is being aided by R and D activities for new technology.

What will be the size of the Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation

This report extensively covers market segmentation by type (monoclonal antibodies, cancer vaccines, check point inhibitors, and immunomodulatory), application (lung cancer, breast cancer, colorectal cancer, and others), and geography (North America, Europe, Asia, and ROW).

By Type

The market share growth by the monoclonal antibodies segment will be significant during the forecast period. There has been a significant increase in the incidence of cancers globally. Monoclonal antibodies are used for the diagnosis and treatment of many diseases, including some types of cancer. They may be used alone, or they may be carried directly to cancer cells by drugs, toxins, or radioactive substances.

Get a glance at the market contribution of various segments View a PDF Sample

The monoclonal antibodies segment was valued at USD 34.49 billion in 2017. In recent years, cancer treatment has been revolutionized by introducing several agents, such as monoclonal antibodies. As this is a cost-effective treatment, several distributors are developing it. Therefore, such factors will drive the growth of the monoclonal antibodies segment in the global immunotherapy market during the forecast period.

By Application

Lung cancer

Lung cancer is a type of cancer that generally begins in the lungs and might spread to lymph nodes or other organs in the body. Factors like increases in smoking, radiation therapy, and others increase the risk factors and the chances of occurrence of lung cancer. One of the most prevalent types of cancer, lung cancer is the main reason for cancer deaths worldwide. Cancer immunotherapy helps in helps in controlling symptoms of advanced or metastatic lung cancer, and also kills cancer cells, and stops lung cancer cells from growing and spreading. The demand for cancer immunotherapy is rising due to rising cigarette usage and lung cancer prevalence worldwide. Therefore, the lung cancer segment will grow in the market during the forecast period.

Breast cancer

Breast cancer is a type of cancer that develops in the breast cells and progresses in stages. Breast cancer is the most common cancer diagnosed in women in the US. It is typically brought on by hormonal fluctuations, family history, lifestyle choices like drinking too much alcohol, and environmental factors like radiation exposure. Cancer immunotherapy plays a major role in treating breast cancers. It is the best-suited therapy for some of the common types of breast cancers, such as recurring, metastatic, and triple-negative breast cancer. They target certain proteins found on the surface of breast cancer cells and also try to revive T cells' original ability to combat breast cancer cells. The increasing number of breast cancer cases globally will drive the growth of the market. therefore, the segment will grow significantly in the market during the forecast period.

By Region

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America holds the largest share of the market owing to the vast investments made in the oncology sector in the US. The US dominates the regional market and acts as the primary revenue generator, followed by Canada. Significant factors supporting the US dominance in this part of the world as well as worldwide are, for example, significant investments in the pharmaceuticals sector, with an emphasis on oncology.

Moreover, Cancer is one of the most common chronic diseases in the US. Thus, with the growing incidences of cancer, companies will invest in extensive research to develop effective drugs to treat several cancers. As cancer drugs are associated with several side effects, the demand is expected to increase in the region during the forecast period.

Buy Now Full Report and Discover More

Key Cancer Immunotherapy Market Players

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Amgen Inc. - The company offers cancer immunotherapy solutions such as Oncolytic Immunotherapy, Amgen Oncology

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The market is fueled by increasing awareness programs and government supervision, which are driving stringent regulations to ensure patient safety. Clinical trials play a crucial role in developing these therapies, despite their high product developmental cost. The market offers significant investment pockets for pharmaceutical companies, hospitals, and cancer research centers. Biologic therapies, including cytokines & immunomodulators and novel drugs like Quizartinib (Vanflyta) targeting FLT3, are at the forefront of this innovative approach, with many treatments showing promising results and gaining approval from regulatory bodies like the FDA. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.

Key Market Drivers

The high prevalence of cancer is driving growth in the market. Poor unhealthy habits, inactivity, and excessive use of tobacco and alcohol can lead to lung, stomach, kidney, head, neck, and larynx cancer. Exposure to ionizing radiations, chemical mutagens, infectious micro-organisms, and environmental pollutants can also contribute to the development of cancer.Additionally, with the aging population and a higher incidence of cancer, the costs associated with diagnosis and treatment are expected to increase. The adoption of new, more expensive treatments as the standard of care will also contribute to this cost escalation. This underscores the importance of awareness programs, stringent regulations, and government supervision in managing these costs. Clinical trials and product developmental costs for treatments such as cytokines & immunomodulators are also significant factors. Hospitals and cancer research centers play crucial roles in addressing these challenges. To provide better treatment options, medical facilities require sensitive and reliable diagnostics for accurate and early cancer detection. Molecular and companion diagnostics are popular methods for detecting various cancer types.

Significant Market Trends

The adoption of various strategies for market growth is a key trend in a significant market. To increase market share, suppliers are implementing various strategies. They form licensing agreements with other companies to commercialize their products worldwide, particularly in emerging countries.

Moreover, the companies have undertaken to collaborate or acquire to increase the global market share of cancer immunotherapies by using the technologies. companies also engage in capital investment and avail government support to develop and launch advanced or upgraded devices.

Major Market Challenges

The presence of stringent regulatory policies is a major challenge in the market. The challenge to the growth of the cancer immunotherapies market is that there are strict regulations introduced by regulatory bodies all over the world. The US FDA has imposed stringent restrictions on the marketing approval and manufacturing of biosimilars.

However, the most important aspect is to provide a combination of biological, physicochemical, and clinical data, which are not required for novel drugs to demonstrate similarity with reference originators. Other details that companies must submit include dosage, route of administration, contraindications, warnings, and precautions, which, in turn, incur a high financial burden on the R&D of cancer immunotherapy.

Buy Now Full Report and Discover More

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.

Type Outlook
- Monoclonal antibodies
- Checkpoint inhibitors and immunomodulators
- Cancer vaccines

Application Outlook
- Lung cancer
- Breast cancer
- Colorectal cancer
- Others

Region Outlook
- North America
  - The U.S.
  - Canada
- Europe
  - The U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
- Rest of The World
  - Australia
  - Argentina
  - Rest of the world

Market Analyst Overview

The market is experiencing significant growth, driven by advancements in techniques that leverage the immune system to target cancer-specific targets. This approach is revolutionizing healthcare expenditure and medical insurance, offering promising outcomes for patients. Technological advancements have led to novel therapies for various cancers like melanoma, prostate cancer, and head & neck cancer, enhancing treatment options. Biologic therapy and the use of live viruses in treatment, such as AML and FMS, are at the forefront of R&D activities. Companies like Immatics and Moderna are pioneering strategic business planning for the development of therapies like PRAME203 TCRT and MARTE mRNA cancer vaccine. With a focus on geriatric populations and those with chronic orthopedic conditions, the market is poised for further growth, supported by advanced medical facilities and the utilization of cancer immunotherapy.

The market is influenced by rising new cases of cancer and deaths due to cancer, driving the need for effective treatments. Clinics play a crucial role in administering these therapies, enhancing immunity against diseases like AML and FMS. Organizations like the International Agency for Research on Cancer (IARC) contribute to research and development in this field.

Market Scope
Report Coverage	Details
Page number	168
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 7.42%
Market growth 2023-2027	USD 38.57 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	6.72
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 41%
Key countries	US, Canada, Germany, France, and China
Competitive landscape	Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks
Key companies profiled	Amgen Inc., Amneal Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Dendreon Pharmaceuticals LLC, Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Gilead Sciences Inc., GlaxoSmithKline Plc, Immunocore Holdings Plc, Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, Seagen Inc., and Takeda Pharmaceutical Co. Ltd.
Market dynamics	Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
Precise estimation of the size of the market size and its contribution to the parent market
Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Application
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2022

3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global cancer immunotherapy market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on global cancer immunotherapy market 2017 - 2021 ($ billion)

4.2 Type Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Type Segment 2017 - 2021 ($ billion)

4.3 Application Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Application Segment 2017 - 2021 ($ billion)

4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)

4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Type

6.1 Market segments
- Exhibit 30: Chart on Type - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Type - Market share 2022-2027 (%)

6.2 Comparison by Type
- Exhibit 32: Chart on Comparison by Type
- Exhibit 33: Data Table on Comparison by Type

6.3 Monoclonal antibodies - Market size and forecast 2022-2027
- Exhibit 34: Chart on Monoclonal antibodies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 35: Data Table on Monoclonal antibodies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 36: Chart on Monoclonal antibodies - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Monoclonal antibodies - Year-over-year growth 2022-2027 (%)

6.4 Check point inhibitors and immunomodulators - Market size and forecast 2022-2027
- Exhibit 38: Chart on Check point inhibitors and immunomodulators - Market size and forecast 2022-2027 ($ billion)
- Exhibit 39: Data Table on Check point inhibitors and immunomodulators - Market size and forecast 2022-2027 ($ billion)
- Exhibit 40: Chart on Check point inhibitors and immunomodulators - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Check point inhibitors and immunomodulators - Year-over-year growth 2022-2027 (%)

6.5 Cancer vaccines - Market size and forecast 2022-2027
- Exhibit 42: Chart on Cancer vaccines - Market size and forecast 2022-2027 ($ billion)
- Exhibit 43: Data Table on Cancer vaccines - Market size and forecast 2022-2027 ($ billion)
- Exhibit 44: Chart on Cancer vaccines - Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on Cancer vaccines - Year-over-year growth 2022-2027 (%)

6.6 Market opportunity by Type
- Exhibit 46: Market opportunity by Type ($ billion)
- Exhibit 47: Data Table on Market opportunity by Type ($ billion)

7 Market Segmentation by Application

7.1 Market segments
- Exhibit 48: Chart on Application - Market share 2022-2027 (%)
- Exhibit 49: Data Table on Application - Market share 2022-2027 (%)

7.2 Comparison by Application
- Exhibit 50: Chart on Comparison by Application
- Exhibit 51: Data Table on Comparison by Application

7.3 Lung cancer - Market size and forecast 2022-2027
- Exhibit 52: Chart on Lung cancer - Market size and forecast 2022-2027 ($ billion)
- Exhibit 53: Data Table on Lung cancer - Market size and forecast 2022-2027 ($ billion)
- Exhibit 54: Chart on Lung cancer - Year-over-year growth 2022-2027 (%)
- Exhibit 55: Data Table on Lung cancer - Year-over-year growth 2022-2027 (%)

7.4 Breast cancer - Market size and forecast 2022-2027
- Exhibit 56: Chart on Breast cancer - Market size and forecast 2022-2027 ($ billion)
- Exhibit 57: Data Table on Breast cancer - Market size and forecast 2022-2027 ($ billion)
- Exhibit 58: Chart on Breast cancer - Year-over-year growth 2022-2027 (%)
- Exhibit 59: Data Table on Breast cancer - Year-over-year growth 2022-2027 (%)

7.5 Colorectal cancer - Market size and forecast 2022-2027
- Exhibit 60: Chart on Colorectal cancer - Market size and forecast 2022-2027 ($ billion)
- Exhibit 61: Data Table on Colorectal cancer - Market size and forecast 2022-2027 ($ billion)
- Exhibit 62: Chart on Colorectal cancer - Year-over-year growth 2022-2027 (%)
- Exhibit 63: Data Table on Colorectal cancer - Year-over-year growth 2022-2027 (%)

7.6 Others - Market size and forecast 2022-2027
- Exhibit 64: Chart on Others - Market size and forecast 2022-2027 ($ billion)
- Exhibit 65: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
- Exhibit 66: Chart on Others - Year-over-year growth 2022-2027 (%)
- Exhibit 67: Data Table on Others - Year-over-year growth 2022-2027 (%)

7.7 Market opportunity by Application
- Exhibit 68: Market opportunity by Application ($ billion)
- Exhibit 69: Data Table on Market opportunity by Application ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 71: Chart on Market share by geography 2022-2027 (%)
- Exhibit 72: Data Table on Market share by geography 2022-2027 (%)

9.2 Geographic comparison
- Exhibit 73: Chart on Geographic comparison
- Exhibit 74: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2022-2027
- Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ billion)
- Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
- Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%)

9.4 Europe - Market size and forecast 2022-2027
- Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
- Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
- Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)

9.5 Asia - Market size and forecast 2022-2027
- Exhibit 83: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
- Exhibit 84: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
- Exhibit 85: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on Asia - Year-over-year growth 2022-2027 (%)

9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
- Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
- Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

9.7 US - Market size and forecast 2022-2027
- Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ billion)
- Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ billion)
- Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%)

9.8 Germany - Market size and forecast 2022-2027
- Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
- Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
- Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)

9.9 China - Market size and forecast 2022-2027
- Exhibit 99: Chart on China - Market size and forecast 2022-2027 ($ billion)
- Exhibit 100: Data Table on China - Market size and forecast 2022-2027 ($ billion)
- Exhibit 101: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 102: Data Table on China - Year-over-year growth 2022-2027 (%)

9.10 France - Market size and forecast 2022-2027
- Exhibit 103: Chart on France - Market size and forecast 2022-2027 ($ billion)
- Exhibit 104: Data Table on France - Market size and forecast 2022-2027 ($ billion)
- Exhibit 105: Chart on France - Year-over-year growth 2022-2027 (%)
- Exhibit 106: Data Table on France - Year-over-year growth 2022-2027 (%)

9.11 Canada - Market size and forecast 2022-2027
- Exhibit 107: Chart on Canada - Market size and forecast 2022-2027 ($ billion)
- Exhibit 108: Data Table on Canada - Market size and forecast 2022-2027 ($ billion)
- Exhibit 109: Chart on Canada - Year-over-year growth 2022-2027 (%)
- Exhibit 110: Data Table on Canada - Year-over-year growth 2022-2027 (%)

9.12 Market opportunity by geography
- Exhibit 111: Market opportunity by geography ($ billion)
- Exhibit 112: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 113: Impact of drivers and challenges in 2022 and 2027

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 114: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 115: Overview on factors of disruption

11.4 Industry risks
- Exhibit 116: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 117: Vendors covered

12.2 Market positioning of vendors
- Exhibit 118: Matrix on vendor position and classification

12.3 Amgen Inc.
- Exhibit 119: Amgen Inc. - Overview
- Exhibit 120: Amgen Inc. - Product / Service
- Exhibit 121: Amgen Inc. - Key offerings

12.4 AstraZeneca Plc
- Exhibit 122: AstraZeneca Plc - Overview
- Exhibit 123: AstraZeneca Plc - Product / Service
- Exhibit 124: AstraZeneca Plc - Key news
- Exhibit 125: AstraZeneca Plc - Key offerings

12.5 Bayer AG
- Exhibit 126: Bayer AG - Overview
- Exhibit 127: Bayer AG - Business segments
- Exhibit 128: Bayer AG - Key news
- Exhibit 129: Bayer AG - Key offerings
- Exhibit 130: Bayer AG - Segment focus

12.6 Bristol Myers Squibb Co.
- Exhibit 131: Bristol Myers Squibb Co. - Overview
- Exhibit 132: Bristol Myers Squibb Co. - Product / Service
- Exhibit 133: Bristol Myers Squibb Co. - Key news
- Exhibit 134: Bristol Myers Squibb Co. - Key offerings

12.7 Eli Lilly and Co.
- Exhibit 135: Eli Lilly and Co. - Overview
- Exhibit 136: Eli Lilly and Co. - Product / Service
- Exhibit 137: Eli Lilly and Co. - Key news
- Exhibit 138: Eli Lilly and Co. - Key offerings

12.8 F. Hoffmann La Roche Ltd.
- Exhibit 139: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 140: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 141: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 142: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 143: F. Hoffmann La Roche Ltd. - Segment focus

12.9 Gilead Sciences Inc.
- Exhibit 144: Gilead Sciences Inc. - Overview
- Exhibit 145: Gilead Sciences Inc. - Product / Service
- Exhibit 146: Gilead Sciences Inc. - Key news
- Exhibit 147: Gilead Sciences Inc. - Key offerings

12.10 GlaxoSmithKline Plc
- Exhibit 148: GlaxoSmithKline Plc - Overview
- Exhibit 149: GlaxoSmithKline Plc - Business segments
- Exhibit 150: GlaxoSmithKline Plc - Key news
- Exhibit 151: GlaxoSmithKline Plc - Key offerings
- Exhibit 152: GlaxoSmithKline Plc - Segment focus

12.11 Immunocore Holdings Plc
- Exhibit 153: Immunocore Holdings Plc - Overview
- Exhibit 154: Immunocore Holdings Plc - Product / Service
- Exhibit 155: Immunocore Holdings Plc - Key offerings

12.12 Johnson and Johnson
- Exhibit 156: Johnson and Johnson - Overview
- Exhibit 157: Johnson and Johnson - Business segments
- Exhibit 158: Johnson and Johnson - Key news
- Exhibit 159: Johnson and Johnson - Key offerings
- Exhibit 160: Johnson and Johnson - Segment focus

12.13 Merck KGaA
- Exhibit 161: Merck KGaA - Overview
- Exhibit 162: Merck KGaA - Business segments
- Exhibit 163: Merck KGaA - Key news
- Exhibit 164: Merck KGaA - Key offerings
- Exhibit 165: Merck KGaA - Segment focus

12.14 Novartis AG
- Exhibit 166: Novartis AG - Overview
- Exhibit 167: Novartis AG - Business segments
- Exhibit 168: Novartis AG - Key offerings
- Exhibit 169: Novartis AG - Segment focus

12.15 Pfizer Inc.
- Exhibit 170: Pfizer Inc. - Overview
- Exhibit 171: Pfizer Inc. - Product / Service
- Exhibit 172: Pfizer Inc. - Key news
- Exhibit 173: Pfizer Inc. - Key offerings

12.16 Sanofi
- Exhibit 174: Sanofi - Overview
- Exhibit 175: Sanofi - Business segments
- Exhibit 176: Sanofi - Key news
- Exhibit 177: Sanofi - Key offerings
- Exhibit 178: Sanofi - Segment focus

12.17 Takeda Pharmaceutical Co. Ltd.
- Exhibit 179: Takeda Pharmaceutical Co. Ltd. - Overview
- Exhibit 180: Takeda Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 181: Takeda Pharmaceutical Co. Ltd. - Key news
- Exhibit 182: Takeda Pharmaceutical Co. Ltd. - Key offerings

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 183: Inclusions checklist
- Exhibit 184: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 185: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 186: Research methodology
- Exhibit 187: Validation techniques employed for market sizing
- Exhibit 188: Information sources

13.5 List of abbreviations
- Exhibit 189: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

cancer immunotherapy market market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis